1. Home
  2. DCO vs SLN Comparison

DCO vs SLN Comparison

Compare DCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCO
  • SLN
  • Stock Information
  • Founded
  • DCO 1849
  • SLN 1994
  • Country
  • DCO United States
  • SLN United Kingdom
  • Employees
  • DCO N/A
  • SLN N/A
  • Industry
  • DCO Military/Government/Technical
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCO Industrials
  • SLN Health Care
  • Exchange
  • DCO Nasdaq
  • SLN Nasdaq
  • Market Cap
  • DCO 1.4B
  • SLN 268.8M
  • IPO Year
  • DCO N/A
  • SLN N/A
  • Fundamental
  • Price
  • DCO $92.07
  • SLN $4.73
  • Analyst Decision
  • DCO Strong Buy
  • SLN Buy
  • Analyst Count
  • DCO 4
  • SLN 5
  • Target Price
  • DCO $119.75
  • SLN $32.60
  • AVG Volume (30 Days)
  • DCO 100.6K
  • SLN 50.2K
  • Earning Date
  • DCO 11-06-2025
  • SLN 11-13-2025
  • Dividend Yield
  • DCO N/A
  • SLN N/A
  • EPS Growth
  • DCO 73.00
  • SLN N/A
  • EPS
  • DCO 2.65
  • SLN N/A
  • Revenue
  • DCO $795,078,000.00
  • SLN $27,169,000.00
  • Revenue This Year
  • DCO $6.15
  • SLN N/A
  • Revenue Next Year
  • DCO $8.02
  • SLN N/A
  • P/E Ratio
  • DCO $34.59
  • SLN N/A
  • Revenue Growth
  • DCO 2.42
  • SLN 22.28
  • 52 Week Low
  • DCO $51.76
  • SLN $1.97
  • 52 Week High
  • DCO $95.93
  • SLN $20.48
  • Technical
  • Relative Strength Index (RSI)
  • DCO 53.84
  • SLN 41.23
  • Support Level
  • DCO $88.84
  • SLN $4.77
  • Resistance Level
  • DCO $94.46
  • SLN $5.80
  • Average True Range (ATR)
  • DCO 2.17
  • SLN 0.36
  • MACD
  • DCO -0.03
  • SLN -0.03
  • Stochastic Oscillator
  • DCO 45.56
  • SLN 22.46

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: